"hemoccult, hemoccolt sesna "
"נובולוג בע""מ" - אחות - test for detection of fecal occult blood
system for carrying out diagnostic in vitro tests in the body's fluid
טבע מדיקל (שיווק) בע"מ - צוות טכני - in-vitro diagnostic tests
hemoccult, hemoccolt sesna
נובולוג בע"מ - אחות - test for detection of fecal occult blood
navios flow cytometer
רניום בע"מ ציוד מעבדות ודיאגנוסטיקה - מומחה - איפיון ואיבחון של מחלות דם ומחלות שבאות לידי ביטוי בשינויים בנוזלי הגוף
navios flow cytometer
רניום בע"מ ציוד מעבדות ודיאגנוסטיקה - מומחה - איפיון ואיבחון של מחלות דם ומחלות שבאות לידי ביטוי בשינויים בנוזלי הגוף
קסמיאול
dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as hydrate - ג'ל - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as hydrate 50 mcg / 1 g - betamethasone - betamethasone - topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.
סנדוסטטין 30 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.
סנדוסטטין 20 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.
סנדוסטטין 10 מג lar
novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.